Related to Parexel, Asan Medical Center Ally to Provide Clinical Trials Services throughout Asia

• Eisai and TSD to Jointly Develop FDA-Approved Cutaneous T-cell Lymphoma Drug in Japan
  
• PPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics
  
• Simcere Fortifies Stake in Chinese H1N1 Vaccine Firm to Over 50%
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• Astellas Enters Asian Licensing Agreement for Ironwood’s Phase III IBS Therapy with $30M
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Spectrum and Handok Sign South Korean Development and Commercialization Deal for Apaziquone
  
• Millipore Acquires Remaining Ownership of India JV
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• Pfizer and Crown Team Up to Develop Treatments for Asian Cancers
  
• Kyowa Hakko Licenses Late-Stage Chronic Kidney Disease Drug from Reata for $35M
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• Qiagen and WuXi Join Forces to Support Biomarker Development in Asia
  
• CLC bio to Provide Next-Generation Sequencing Solutions in Japan Through Filgen
  
• Veritas to Distribute ZyGem’s DNA Extraction Kits in Japan